MCID: CHL152
MIFTS: 50

Childhood Acute Lymphocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Childhood Acute Lymphocytic Leukemia

MalaCards integrated aliases for Childhood Acute Lymphocytic Leukemia:

Name: Childhood Acute Lymphocytic Leukemia 12 53 15
Childhood Acute Lymphoblastic Leukemia 12 53 15
Pediatric Acute Lymphoblastic Leukemia 53
Childhood All 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0080144
NCIt 50 C3168

Summaries for Childhood Acute Lymphocytic Leukemia

NIH Rare Diseases : 53 Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow, and the most common type of cancer in children. In children with this condition, too many stem cells made by the bone marrow become lymphoblasts, B lymphocytes, or T lymphocytes. These cells do not function normally and have trouble fighting off infections. Signs and symptoms may include fever; easy bruising or bleeding; bone or joint pain; painless lumps in the neck, underarm, stomach, or groin; weakness; fatigue; and/or loss of appetite. Treatment depends on several factors and may include combination chemotherapy, targeted therapy, and/or stem cell transplant. On August 30 2017, Kymriah became the first gene therapy approved by the FDA. Kymriah is now an option for children and young adults up to 25 years old with B-Cell precursor ALL that has proven resistant to other treatments or has relapsed two or more times.

MalaCards based summary : Childhood Acute Lymphocytic Leukemia, also known as childhood acute lymphoblastic leukemia, is related to b-cell childhood acute lymphoblastic leukemia and osteonecrosis. An important gene associated with Childhood Acute Lymphocytic Leukemia is PAX8-AS1 (PAX8 Antisense RNA 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MicroRNAs in cancer. The drugs Thiotepa and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 An acute lymphocytic leukemia occuring during childhood.

Related Diseases for Childhood Acute Lymphocytic Leukemia

Diseases related to Childhood Acute Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 384)
# Related Disease Score Top Affiliating Genes
1 b-cell childhood acute lymphoblastic leukemia 33.9 IKZF1 ETV6 CEBPE
2 osteonecrosis 31.3 VEGFA MTHFR ABCB1
3 lymphocytic leukemia 30.9 MCL1 IKZF1 ETV6 BCL2
4 lymphoma, non-hodgkin, familial 30.5 MCL1 BCL2 BAX ABCB1
5 leukemia, chronic lymphocytic 30.5 MCL1 BCL2 BAX ABCB1
6 leukemia, acute myeloid 30.4 MCL1 ETV6 CEBPE ABCB1
7 mucositis 30.4 VEGFA MTHFR ABCB1
8 acute leukemia 30.2 MTHFR ETV6 ABCB1
9 childhood leukemia 30.0 PBX1 MTHFR ETV6 ARID5B
10 precursor t-cell acute lymphoblastic leukemia 29.8 IKZF1 ETV6 BAX
11 leukemia, acute lymphoblastic 3 29.5 PBX1 IKZF1 ETV6
12 leukemia, chronic myeloid 29.3 MCL1 IKZF1 ETV6 ABCB1
13 myeloma, multiple 28.9 VEGFA MCL1 IKZF1 FGF2 ABCB1
14 hematologic cancer 28.4 VEGFA NR3C1 MCL1 IKZF1 ETV6 BAX
15 t-cell childhood acute lymphocytic leukemia 12.5
16 leukemia 10.7
17 hematopoietic stem cell transplantation 10.6
18 chromosomal triplication 10.5
19 splenomegaly 10.5
20 hemifacial spasm 10.5 VEGFA MTHFR
21 severe combined immunodeficiency 10.5
22 lipid metabolism disorder 10.5
23 leukemia, acute lymphoblastic 10.4
24 retinoblastoma 10.4
25 graft-versus-host disease 10.4
26 testicular leukemia 10.4
27 central nervous system disease 10.4
28 familial retinoblastoma 10.4
29 nervous system disease 10.4
30 bone mineral density quantitative trait locus 3 10.4
31 acute t cell leukemia 10.4
32 neuropathy 10.4
33 47,xyy 10.4
34 acute graft versus host disease 10.4
35 soft tissue sarcoma 10.3 VEGFA BCL2 ABCB1
36 kashin-beck disease 10.3 VEGFA BCL2 BAX
37 malignant teratoma 10.3 BCL2 BAX
38 body mass index quantitative trait locus 1 10.3
39 lymphoblastic lymphoma 10.3
40 peripheral nervous system disease 10.3
41 leukemia, b-cell, chronic 10.3
42 gastric lymphoma 10.3 VEGFA BCL2 BAX
43 lymphoma, hodgkin, classic 10.3
44 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
45 body mass index quantitative trait locus 11 10.3
46 wilms tumor 1 10.2
47 allergic rhinitis 10.2
48 pollen allergy 10.2
49 hyperparathyroidism 10.2
50 dermatitis 10.2

Graphical network of the top 20 diseases related to Childhood Acute Lymphocytic Leukemia:



Diseases related to Childhood Acute Lymphocytic Leukemia

Symptoms & Phenotypes for Childhood Acute Lymphocytic Leukemia

MGI Mouse Phenotypes related to Childhood Acute Lymphocytic Leukemia:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 ARID5B BAX BCL2 CEBPE ETV6 FGF2
2 hematopoietic system MP:0005397 10.21 ABCB1 ARID5B BAX BCL2 CEBPE ETV6
3 endocrine/exocrine gland MP:0005379 10.16 ABCB1 ARID5B BAX BCL2 ETV6 IKZF1
4 immune system MP:0005387 10.14 ABCB1 ARID5B BAX BCL2 CEBPE ETV6
5 digestive/alimentary MP:0005381 10.13 ABCB1 ARID5B BCL2 CEBPE ETV6 IKZF1
6 mortality/aging MP:0010768 10.13 ABCB1 ARID5B BAX BCL2 CEBPE ETV6
7 integument MP:0010771 10.02 BCL2 CEBPE ETV6 IKZF1 MCL1 MTHFR
8 muscle MP:0005369 9.8 ARID5B BAX BCL2 FGF2 NR3C1 PBX1
9 reproductive system MP:0005389 9.65 ABCB1 ARID5B BAX BCL2 FGF2 MCL1
10 neoplasm MP:0002006 9.63 BAX BCL2 ETV6 FGF2 IKZF1 VEGFA
11 skeleton MP:0005390 9.23 ARID5B BAX CEBPE FGF2 MTHFR NR3C1

Drugs & Therapeutics for Childhood Acute Lymphocytic Leukemia

Drugs for Childhood Acute Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Oprelvekin Approved, Investigational Phase 4 145941-26-0
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Ethylene Phase 4 74-85-1 6325
6
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
8
Mercaptopurine Approved Phase 3 50-44-2 667490
9
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
10
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
12
Calcium carbonate Approved, Investigational Phase 3 471-34-1
13
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
14
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
17
Ifosfamide Approved Phase 3 3778-73-2 3690
18
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
19
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
20
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
21
Acyclovir Approved Phase 3 59277-89-3 2022
22
Ondansetron Approved Phase 3 99614-02-5 4595
23
Tazobactam Approved Phase 3 89786-04-9 123630
24
Piperacillin Approved Phase 3 66258-76-2 43672
25
Vancomycin Approved Phase 3 1404-90-6 441141 14969
26
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
27
Ribavirin Approved Phase 3 36791-04-5 37542
28
Palivizumab Approved, Investigational Phase 3 188039-54-5
29
Captopril Approved Phase 3 62571-86-2 44093
30
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
31
Dasatinib Approved, Investigational Phase 2, Phase 3 302962-49-8 3062316
32
Ichthammol Approved Phase 2, Phase 3 8029-68-3
33
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
34
Etoposide Approved Phase 3 33419-42-0 36462
35
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
36
Mesna Approved, Investigational Phase 3 3375-50-6 598
37
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
38
Busulfan Approved, Investigational Phase 3 55-98-1 2478
39
Mycophenolic acid Approved Phase 3 24280-93-1 446541
40
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
41
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
43
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
44
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
46
Emodepside Investigational, Vet_approved Phase 2, Phase 3 155030-63-0
47
Cortisone Experimental Phase 3 53-06-5 222786
48 BB 1101 Phase 2, Phase 3
49 Antidotes Phase 3
50 Alkylating Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 346)
# Name Status NCT ID Phase Drugs
1 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
2 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
3 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
4 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
5 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
6 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
7 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
9 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
10 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
11 TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS Unknown status NCT00002499 Phase 2, Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;dexamethasone;methotrexate;prednisone;vincristine sulfate
12 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
13 A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
14 Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial Unknown status NCT00003437 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate
15 Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial Completed NCT00186901 Phase 3 Calcium carbonate (Tums), vitamin D
16 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
17 Nordic Society of Paediatric Haematology and Oncology Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults (18-45 Years of Age) With ALL. Efficacy of Individualised 6MP Dosing During Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
18 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
19 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
20 EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY Completed NCT00002816 Phase 3 cytarabine;dexamethasone;etoposide;idarubicin;ifosfamide;leucovorin calcium;mesna;pegaspargase;therapeutic hydrocortisone;thioguanine;vincristine sulfate;Methotrexate
21 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
22 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion Completed NCT00819351 Phase 3 PEG Asparaginase at six weeks interval;PEG Asparaginase at two weeks interval
23 ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
24 ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study Completed NCT00005585 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
25 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
26 Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study Completed NCT00002812 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;idarubicin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
27 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
28 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
29 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
30 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
31 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
32 ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study Completed NCT00005603 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate
33 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
34 Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00005945 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
35 A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia Completed NCT01829711 Phase 3 Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
36 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
37 Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia Completed NCT00002744 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisone;therapeutic hydrocortisone;thioguanine;vincristine sulfate
38 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
39 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
40 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
41 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
42 High Risk B-Precursor Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
43 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
44 International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia Completed NCT00015873 Phase 3 asparaginase;cytarabine;mercaptopurine;methotrexate;prednisolone;vincristine sulfate
45 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
46 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
47 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
48 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia Completed NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
49 FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study Completed NCT00002757 Phase 3 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;methotrexate;prednisolone;prednisone;therapeutic hydrocortisone;vincristine sulfate
50 AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine

Search NIH Clinical Center for Childhood Acute Lymphocytic Leukemia

Genetic Tests for Childhood Acute Lymphocytic Leukemia

Anatomical Context for Childhood Acute Lymphocytic Leukemia

MalaCards organs/tissues related to Childhood Acute Lymphocytic Leukemia:

41
Bone, Bone Marrow, T Cells, B Cells, Myeloid, Brain, Testes

Publications for Childhood Acute Lymphocytic Leukemia

Articles related to Childhood Acute Lymphocytic Leukemia:

(show top 50) (show all 3386)
# Title Authors PMID Year
1
Time course of peripheral blood count recovery during induction chemotherapy for childhood acute lymphoblastic leukemia. 38
31126219 2019
2
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. 38
31102422 2019
3
ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis. 38
31111395 2019
4
Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors. 38
30778669 2019
5
Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia. 38
31407461 2019
6
The relationship of child executive functions to parenting capacities in childhood acute lymphoblastic leukemia survivors. 38
31033172 2019
7
Long-Term Outcomes of Modified St Jude Children's Research Hospital Total Therapy XIIIB and XV Protocols for Thai Children With Acute Lymphoblastic Leukemia. 38
31103474 2019
8
Minimal Residual Disease-guided Risk Restratification and Therapy Improves the Survival of Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Children's Hospital in China. 38
30640823 2019
9
The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial. 38
28853979 2019
10
Visual short-term memory activation patterns in adult survivors of childhood acute lymphoblastic leukemia. 38
31310324 2019
11
HOGG1 rs1052133 Genotypes and Risk of Childhood Acute Lymphoblastic Leukemia in a Taiwanese Population. 38
31280195 2019
12
Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia. 38
31280227 2019
13
Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. 38
31010660 2019
14
Tobacco smoke exposure and the risk of childhood acute lymphoblastic leukemia and acute myeloid leukemia: A meta-analysis. 38
31305478 2019
15
Meningioma Screening With MRI in Childhood Leukemia Survivors Treated With Cranial Radiation. 38
30880270 2019
16
Brain morphology and information processing at the completion of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. 38
29969366 2019
17
Childhood Acute Lymphoblastic Leukemia Survivors Have a Substantially Lower Cardiorespiratory Fitness Level than Healthy Canadians Despite a Clinically Equivalent Level of Physical Activity. 38
31287753 2019
18
TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia. 38
31289210 2019
19
ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. 38
30630977 2019
20
Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA - 2009 protocol. 38
31287348 2019
21
Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. 38
31156339 2019
22
Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. 38
30978155 2019
23
Genetic polymorphisms of ARID5B rs7089424 and rs10994982 are associated with B-lineage ALL susceptibility in Chinese pediatric population. 38
31274788 2019
24
Impact of Childhood Leukemia Treatment on Attention Measured by the Continuous Performance Test Factor Structure. 38
31225837 2019
25
Microstructural white matter alterations associated to neurocognitive deficits in childhood leukemia survivors treated with cranial radiotherapy - a diffusional kurtosis study. 38
30747019 2019
26
First Strike-Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction. 38
31221821 2019
27
Impact of myosteatosis in survivors of childhood acute lymphoblastic leukemia. 38
31226904 2019
28
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. 38
31030032 2019
29
Methylation of the promoter region of the MTRR gene in childhood acute lymphoblastic leukemia. 38
31002356 2019
30
RE: "RACIAL AND ETHNIC DIFFERENCES IN SOCIOECONOMIC POSITION AND RISK OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA". 38
30924856 2019
31
Improving survival outcomes of childhood acute lymphoblastic leukemia: A 25-year experience from a single center in Saudi Arabia. 38
31184419 2019
32
Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. 38
31219514 2019
33
A cross-sectional follow-up study of physical morbidities, neurocognitive function, and attention problems in post-treatment childhood acute lymphoblastic leukemia survivors. 38
30913362 2019
34
Is there a relationship between vitamin D nutritional status and metabolic syndrome in childhood acute lymphoblastic leukemia survivors? A PETALE study. 38
31060831 2019
35
Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. 38
30835935 2019
36
Early Infection with Cytomegalovirus and Risk of Childhood Hematologic Malignancies. 38
30996022 2019
37
The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. 38
31078468 2019
38
[Expression and significance of dishevelled proteins in the Wnt pathway in childhood acute lymphoblastic leukemia]. 38
31104653 2019
39
Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors. 38
31055782 2019
40
A genetic variant in miR-100 is a protective factor of childhood acute lymphoblastic leukemia. 38
30848099 2019
41
Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. 38
30690723 2019
42
Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype. 38
30770347 2019
43
Identification and Characterization of Novel Fusion Genes with Potential Clinical Applications in Mexican Children with Acute Lymphoblastic Leukemia. 38
31096545 2019
44
Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors. 38
31088516 2019
45
Bone marrow recovery of hematopoietic stem cells and microenvironment after chemotherapy in childhood acute lymphoblastic leukemia: consecutive observations according to chemotherapy schedule. 38
31313940 2019
46
Homozygous mutation in NUDT15 in childhood acute lymphoblastic leukemia with increased susceptibility to mercaptopurine toxicity: A case report. 38
31007757 2019
47
Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Clinical characteristics, risk factors, course, and outcome of disease. 38
30592147 2019
48
A Case of Miscarriage Caused by a Small Uterus following Childhood Chemotherapy. 38
31275135 2019
49
A Bayesian multivariate latent t-regression model for assessing the association between corticosteroid and cranial radiation exposures and cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia: a PETALE study. 38
31088361 2019
50
Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia. 38
30944321 2019

Variations for Childhood Acute Lymphocytic Leukemia

Copy number variations for Childhood Acute Lymphocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 250737 9 21967751 21994490 Deletion CDKN2A pediatric acute lymphoblastic leukemia

Expression for Childhood Acute Lymphocytic Leukemia

Search GEO for disease gene expression data for Childhood Acute Lymphocytic Leukemia.

Pathways for Childhood Acute Lymphocytic Leukemia

Pathways related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 VEGFA MCL1 FGF2 BCL2 BAX
2 12.33 VEGFA MCL1 BCL2 ABCB1
3 12 PBX1 ETV6 CEBPE BAX
4 11.86 MCL1 BCL2 BAX
5 11.7 VEGFA BCL2 BAX
6 11.68 VEGFA MCL1 FGF2 BCL2
7
Show member pathways
11.61 MCL1 BCL2 BAX
8 11.58 PBX1 NR3C1 BAX
9 11.45 VEGFA MCL1 ABCB1
10 11.29 MCL1 BCL2 BAX
11
Show member pathways
11.21 MCL1 BCL2 BAX
12 11.11 VEGFA MCL1 BAX
13
Show member pathways
10.92 BCL2 BAX
14 10.83 BCL2 BAX
15 10.79 BCL2 BAX ABCB1
17 10.47 MCL1 ETV6 BCL2
18 9.8 BCL2 BAX ABCB1

GO Terms for Childhood Acute Lymphocytic Leukemia

Cellular components related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pore complex GO:0046930 8.96 BCL2 BAX
2 Bcl-2 family protein complex GO:0097136 8.62 MCL1 BAX

Biological processes related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.84 VEGFA MCL1 FGF2 BCL2
2 animal organ morphogenesis GO:0009887 9.76 PBX1 FGF2 BCL2
3 male gonad development GO:0008584 9.73 BCL2 BAX ARID5B
4 post-embryonic development GO:0009791 9.7 BCL2 BAX ARID5B
5 B cell homeostasis GO:0001782 9.62 BCL2 BAX
6 adrenal gland development GO:0030325 9.61 PBX1 ARID5B
7 release of cytochrome c from mitochondria GO:0001836 9.61 BCL2 BAX
8 cell migration involved in sprouting angiogenesis GO:0002042 9.6 VEGFA FGF2
9 apoptotic mitochondrial changes GO:0008637 9.59 BCL2 BAX
10 negative regulation of anoikis GO:2000811 9.58 MCL1 BCL2
11 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.58 MCL1 BCL2 BAX
12 macrophage differentiation GO:0030225 9.57 VEGFA CEBPE
13 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.55 BCL2 BAX
14 branching involved in ureteric bud morphogenesis GO:0001658 9.54 PBX1 FGF2 BCL2
15 regulation of protein heterodimerization activity GO:0043497 9.51 BCL2 BAX
16 ovarian follicle development GO:0001541 9.5 VEGFA BCL2 BAX
17 stem cell proliferation GO:0072089 9.49 FGF2 ABCB1
18 regulation of protein homodimerization activity GO:0043496 9.48 BCL2 BAX
19 kidney development GO:0001822 9.46 VEGFA BCL2 BAX ARID5B
20 leukocyte homeostasis GO:0001776 9.43 BCL2 BAX
21 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.43 MCL1 BCL2 BAX
22 regulation of nitrogen utilization GO:0006808 8.96 BCL2 BAX
23 positive regulation of developmental pigmentation GO:0048087 8.62 BCL2 BAX
24 positive regulation of transcription by RNA polymerase II GO:0045944 10 VEGFA PBX1 NR3C1 IKZF1 FGF2 ETV6

Molecular functions related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.43 VEGFA PBX1 MCL1 CEBPE BCL2 BAX
2 BH3 domain binding GO:0051434 8.8 MCL1 BCL2 BAX

Sources for Childhood Acute Lymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....